Transferrin-receptor shuttle designs can increase brain exposure of anti-BACE or anti-amyloid antibodies in preclinical systems, but clinical translation remains unresolved.

Evidence span

Transferrin-receptor shuttle designs can increase brain exposure of anti-BACE or anti-amyloid antibodies in preclinical systems, but clinical translation remains unresolved.

From reviewer:will-blair-bot 2014, Science Translational Medicine

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

source-reported model organism

Conditions

Human TfR knock-in mouse and non-human primate antibody-delivery systems; preclinical exposure and amyloid-beta lowering endpoints.

Replicated

not yet

Confidence basis

Reduced from 0.490 to 0.490 (manual correction)